media – Page 101 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

International KCL research project to develop SMARTdrugs for aggressive cancers

The platform will be used to diagnose and treat cancers, including lung and brain tumours A new international study led by King’s College London (KCL) researchers is developing a radiotheranostic platform called SMARTdrugs for the diagnosis and treatment of aggressive forms of cancer. With partners in Munich, Zurich, San Sebastian and Utrecht, the study has been awarded a Pathfinder Open Grant of nearly €4m from the European Innovation Council. Aggressive cancers such as lung and brain tumours occur when the growth rate is impacted by the genetic makeup of the tumour and the rate at which the cells are dividing. Researchers aim to create supramolecular compounds as an alternative to the current standard of attaching radionuclides directly to drug molecules to allow clinicians to visualise key signatures of tumours using medical imaging systems. The supramolecular compounds will have greater control over their size, shape and other biochemical properties than other ...
- Source: drugdu
- 68
- June 5, 2024
New UCL-developed immunotherapy shows promising results in treating bone cancer

Bone cancer affects more than 150,000 people in the UK and is often resistant to chemotherapy A new type of immunotherapy developed by researchers from University College London (UCL) has demonstrated promising preclinical results in treating bone cancer. Published in Science Translational Medicine, the OPS-gdT treatment platform outperformed conventional immunotherapy when controlling the growth of osteosarcoma, a form of bone cancer. Affecting more than 150,000 people in the UK, cancer that begins or spreads to the bones is hard to treat as it is frequently resistant to chemotherapy and is the leading cause of cancer-related death. Researchers used a small subset of immune cells known as gamma-delta T (gdT) cells, a type of immune cell that can be made from healthy donor immune cells, to provide an efficient and cost-effective solution for treating this condition. gdT cells work to kill antibody-labelled targets safely from person to person without risking graft-versus-host ...
- Source: drugdu
- 71
- June 5, 2024
Novartis Pivotal Phase III ASC4FIRST Study Provides Efficacy and Safety Data for Scemblix in Newly Diagnosed CML Patients

Novartis recently presented positive results from the pivotal Phase III ASC4FIRST study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting: the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) with Scemblix® at Week 48 demonstrated greater efficacy and safety than the investigator’s choice of tyrosine kinase inhibitors (TKIs) (imatibe Scemblix demonstrated a superior major molecular response (MMR) rate at week 48 than both investigator-selected tyrosine kinase inhibitors (TKIs) (imatinib, nilotinib, dasatinib, and bosutinib) and imatinib alone.Scemblix demonstrated a higher MMR rate at week 48 than the second-generation TKIs (nilotinib, dasatinib, and bosutinib) with higher rate values.The MMR rate was higher than that of the second-generation TKIs. In addition, Scemblix demonstrated a favorable safety and tolerability profile, with fewer adverse events (AEs) and treatment interruptions relative to imatinib and second-generation TKIs. Tim Hughes, M.D., professor at the South Australian ...
- Source: drugdu
- 96
- June 5, 2024
BIO-THERA Receives Positive CHMP Opinion for Bevacizumab Avzivi® in Europe

BIO-THERA Biopharmaceutical Co., Ltd (SSE: 688177) is a global science-based and innovative biopharmaceutical company based in Guangzhou, China, hereinafter referred to as “BIO-THERA” or the “Company”. The Company is committed to developing a new generation of innovative drugs and biosimilars for the treatment of oncology, autoimmune diseases, cardiovascular diseases, ophthalmology and other major diseases that threaten human life or health. The Company today announced that it recently received notification from the European Medicines Agency (EMA) that Avzivi® (BAT1706), a biosimilar developed with reference to Anvitin® (bevacizumab), has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP), which recommended to the European Commission (EC) that it grant marketing authorization for Avzivi® for the treatment of metastatic colorectal cancer, metastatic breast cancer, non-small cell lung cancer, metastatic renal cell carcinoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and metastatic cervical cancer. The CHMP’s opinion on ...
- Source: drugdu
- 63
- June 5, 2024
Microneedle Patch Detects Skin Cancer Early

Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes. Despite its advancements, there has been a lack of progress specifically in the area of cancer, and more notably in skin cancer detection. Researchers have now introduced a novel technique for identifying malignant melanoma, which is the most serious type of skin cancer and also the fastest growing. A groundbreaking study conducted by researchers at Karolinska Institutet (Stockholm, Sweden) led to the development of a new type of patch equipped with microneedles designed to detect the biomarker tyrosinase directly within the skin. Tyrosinase is an enzyme that serves as a crucial biomarker for malignant melanoma. By assessing the enzyme directly in the skin, this approach allows for the rapid detection of changes indicative of the disease. The feasibility of this ...
- Source: drugdu
- 70
- June 4, 2024
Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations, visual evaluations, or immunological tests, all of which depend on the presence of advanced symptoms that might take months or even years to appear. Consequently, many cases remain untreated and undiagnosed early on, complicating treatment and leading to the severe, long-term impacts of Lyme disease. Now, a groundbreaking patented molecular diagnostic kit is poised to provide game-changing autonomous detection of Lyme disease within minutes. Presently, Lyme disease testing methods aim to identify antibodies produced by the body in reaction to the infection. However, since the development of these antibodies can take several weeks, tests performed soon after infection often yield false negatives. En Carta Diagnostics (Paris, France) has developed a molecular diagnostic platform that effectively addresses this issue. This platform, which utilizes a simple ...
- Source: drugdu
- 92
- June 4, 2024
GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO

GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.A GSK multiple myeloma drug that was withdrawn from the market is accumulating new clinical data that could support its return — perhaps as an earlier line of therapy. With the latest results, clinicians and GSK executives say they may have figured out how to address a lingering question about how to safely dose the drug, Blenrep. The new data were presented Sunday during the annual meeting of the American Society of Clinical Oncology in Chicago. Blenrep is an antibody drug conjugate (ADC) that targets the BCMA protein on multiple myeloma cells, delivering to them a payload of toxic chemotherapy. There are many multiple myeloma drugs available, but frequent relapse in this ...
- Source: drugdu
- 115
- June 4, 2024
Scemblix Shows Improved Major Molecular Response Treating Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Don Tracy, Associate Editor Results of a Phase III trial indicated that Scemblix was more effective than standard-of-care tyrosine kinase inhibitors in treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Novartis announced promising results from the Phase III ASC4FIRST trial of Scemblix (asciminib), which showed superiority over standard-of-care tyrosine kinase inhibitors (TKIs) in treating newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). “Patients living with CML need efficacious and well-tolerated treatment options that help them achieve meaningful outcomes as they manage their chronic condition,” said Shreeram Aradhye, MD, president, development, chief medical officer, Novartis, in a press release. “The compelling ASC4FIRST data highlight the potential of Scemblix to achieve better results than standard-of-care in newly diagnosed adults, while maintaining a favorable safety and tolerability profile. These results reinforce Scemblix as a proven treatment in Ph+CML-CP, as we continue to build on ...
- Source: drugdu
- 113
- June 4, 2024
Leads Biolabs’ Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting.

NANJING, China, June 3, 2024 /PRNewswire/ — The annual meeting of the American Society of Clinical Oncology (ASCO) commenced on May 31st, Showcasing groundbreaking cancer research from around the world. According to official information, over 7,000 abstracts were submitted this year. After rigorous evaluation by Scientific Program Committee and ASCO Leadership, LBL-024, a bispecific antibody independently developed by Leads Biolabs with global intellectual property rights, was selected for an oral presentation. Today, Dr. Panpan Zhang, the investigator of LBL-024, presented the outstanding clinical data during the Clinical Science Symposium-Building Novel Antibody-Based Approaches in Gastrointestinal Cancers. This is a phase I/II first in human, open-label, multicenter, dose escalation/expansion study that evaluates the safety and efficacy of LBL-024 monotherapy in patients with advanced malignant tumors and neuroendocrine carcinoma. The study results demonstrated good safety profile and very promising antitumor effects as a monotherapy in patients with advanced malignant tumors, particularly extrapulmonary neuroendocrine ...
- Source: drugdu
- 139
- June 4, 2024
EMA endorses AbbVie’s Skyrizi for ulcerative colitis

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has granted AbbVie’s ulcerative colitis (UC) drug Skyrizi (risankizumab) a positive recommendation for approval. The committee’s recommendation was based on results from two Phase III studies. In the INSPIRE trial (NCT03398148), 20.3% of patients in the Skyrizi treatment group achieved clinical remission, compared to 6.2% in the placebo group. Furthermore, in the Phase III COMMAND study (NCT03398135), 51% of patients treated with Skyrizi 180 mg and 48% of patients treated with Skyrizi 360mg demonstrated endoscopic improvement in week 52. Skyrizi is a monoclonal antibody therapy that inhibits interleukin-23 (IL-23). This reduces anti-inflammatory processes. In the 31 May press release, Dr Edouard Louis, the head of gastroenterology at University Hospital CHU of Liège Belgium said: “These results suggest that risankizumab may help patients coping with the challenging symptoms of ulcerative colitis, which include abdominal pain, bowel urgency and ...
- Source: drugdu
- 110
- June 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.